$5.72
Market Capitalization | 17.5M |
Book Value | $10.68 |
Earnings Per Share (EPS) | -2.31 |
PEG Ratio | 0.0 |
Wall Street Target Price | 15.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -152750.0% |
Return On Assets TTM | -29.96% |
Return On Equity TTM | -81.71% |
Revenue TTM | 2.4M |
Revenue Per Share TTM | 1.96 |
Quarterly Revenue Growth YOY | -99.8% |
Gross Profit TTM | 5.2M |
EBITDA | -19.9M |
Diluted Eps TTM | -2.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 162.24%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 26.9M | ↑ 2812.35% |
Net Income | 4.2M | ↓ 124.93% |
Net Profit Margin | 15.58% | ↑ 1835.3% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 532.0K | ↓ 98.02% |
Net Income | -6.0M | ↓ 244.3% |
Net Profit Margin | -1.1K% | ↓ 1151.29% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.7M | ↑ 586.47% |
Net Income | -5.1M | ↓ 15.29% |
Net Profit Margin | -140.14% | ↑ 995.57% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 5.3M | ↑ 44.03% |
Net Income | -8.4M | ↑ 63.5% |
Net Profit Margin | -159.09% | ↓ 18.95% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 5.6M | ↑ 7.22% |
Net Income | -37.7M | ↑ 350.16% |
Net Profit Margin | -667.89% | ↓ 508.8% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.6M | ↓ 18.79% |
Net Income | -16.9M | ↓ 55.25% |
Net Profit Margin | -367.99% | ↑ 299.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.5M | ↑ 33.6% |
Net Income | -20.9M | ↑ 570.05% |
Net Profit Margin | -841.01% | ↓ 673.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.1M | ↓ 14.37% |
Net Income | -4.4M | ↓ 79.13% |
Net Profit Margin | -204.98% | ↑ 636.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2M | ↑ 5.55% |
Net Income | -2.5M | ↓ 42.27% |
Net Profit Margin | -112.11% | ↑ 92.87% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.0K | ↓ 99.87% |
Net Income | -4.1M | ↑ 64.61% |
Net Profit Margin | -138.2K% | ↓ 138054.56% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 124.3K | ↑ 4044.8% |
Net Income | -5.8M | ↑ 39.7% |
Net Profit Margin | -4.7K% | ↑ 133509.64% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.0M | ↑ 2130.74% |
Net Income | -1.4M | ↓ 67.36% |
Net Profit Margin | -68.14% | ↑ 4588.89% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 25.0M | ↑ 12.69% |
Total Liabilities | 23.1M | ↓ 7.5% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 20.0M | ↓ 20.11% |
Total Liabilities | 22.4M | ↓ 2.86% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 37.3M | ↑ 86.56% |
Total Liabilities | 24.1M | ↑ 7.23% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 80.1M | ↑ 114.88% |
Total Liabilities | 27.1M | ↑ 12.67% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 56.0M | ↓ 30.06% |
Total Liabilities | 20.3M | ↓ 25.32% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 36.8M | ↓ 34.27% |
Total Liabilities | 18.7M | ↓ 7.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 56.0M | ↓ 15.88% |
Total Liabilities | 20.3M | ↑ 17.81% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 51.3M | ↓ 8.47% |
Total Liabilities | 20.1M | ↓ 0.87% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 46.5M | ↓ 9.36% |
Total Liabilities | 17.4M | ↓ 13.3% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 42.5M | ↓ 8.6% |
Total Liabilities | 16.2M | ↓ 6.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 36.8M | ↓ 13.32% |
Total Liabilities | 18.7M | ↑ 15.52% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 21.7M | ↓ 20.14% |
Total Liabilities | 2.5M | ↓ 81.71% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.8M | ↓ 129.79% |
Investing Cash Flow | -35.0K | ↓ 111.4% |
Financing Cash Flow | 3.9M | ↓ 51.52% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.7M | ↓ 257.14% |
Investing Cash Flow | 50.0K | ↓ 242.86% |
Financing Cash Flow | 3.9M | ↑ 0.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↓ 61.5% |
Investing Cash Flow | 56.0K | ↑ 12.0% |
Financing Cash Flow | 20.5M | ↑ 425.76% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.6M | ↑ 107.82% |
Investing Cash Flow | -658.0K | ↓ 1275.0% |
Financing Cash Flow | 51.0M | ↑ 149.35% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.4M | ↓ 13.21% |
Investing Cash Flow | -3.0K | ↓ 40.0% |
Financing Cash Flow | -17.0K | ↓ 48.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↑ 18.6% |
Investing Cash Flow | -3.0K | ↑ 0.0% |
Financing Cash Flow | -38.0K | ↑ 123.53% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.3M | ↑ 5.71% |
Investing Cash Flow | -3.0K | ↑ 0.0% |
Financing Cash Flow | -42.0K | ↑ 10.53% |
Sell
Neutral
Buy
Aeterna Zentaris Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
æterna zentaris inc. (tsx: aez, nasdaq: aezs) is a global biopharmaceutical company focused on endrocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. æterna zentaris inc. (tsx: aez, nasdaq: aezs) est une société biopharmaceutique internationale, spécialisée dans la découverte, le développement et la commercialisation de thérapies en endocrinologie et en oncologie.
Organization | Aeterna Zentaris Inc |
Employees | 0 |
CEO | Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc. |
Industry | Health Technology |
A Spac I Acquisition Corp
$5.72
+0.0%
Keyarch Acquisition Corp
$5.72
+0.0%
Connexa Sports Technologies Inc
$5.72
+0.0%
Us Value Etf
$5.72
+0.0%
First Wave Biopharma Inc
$5.72
+0.0%
Global X Msci Next Emerging
$5.72
+0.0%
Fat Projects Acquisition Corp
$5.72
+0.0%
Capital Link Global Fintech
$5.72
+0.0%
Applied Uv Inc
$5.72
+0.0%